Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Active ingredients: aflibercept
What it is used for
EYLEA (aflibercept) is indicated in adults for the treatment of: - neovascular (wet) age-related macular degeneration (wet AMD); - visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO); - diabetic macular oedema (DME); - visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO); - visual impairment due to myopic choroidal neovascularisation (myopic CNV)
How to take it
The way to take this medicine is: Intravitreal-Within The Vitreous Cavity Of The Eye.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Protect from Light
- Shelf lifetime is 24 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
EYLEA is a sterile, clear, colourless to pale yellow, preservative-free, iso-osmotic aqueous 40 mg/mL solution for intravitreal injection.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on February 1, 2019. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient aflibercept
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Retinopathy in diabetes (diabetic retinopathy)
Diabetic retinopathy is one of the most common complications of diabetes. People with retinopathy have damaged blood vessels in theretina (the light-sensitive layer at the back of the eyes).
Read more on myDr website
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion | Cochrane
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion
Read more on Cochrane (Australasian Centre) website